What is the expected growth forecast for the T Cell Specific Surface Glycoprotein CD28 market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing research.

What are the key drivers of the T Cell Specific Surface Glycoprotein CD28 market?

Key drivers include rising demand for immunotherapies and growing investment in cancer research.

What are the major challenges facing the T Cell Specific Surface Glycoprotein CD28 market?

Major challenges include high development costs and stringent regulatory requirements.

Which regions are expected to lead the T Cell Specific Surface Glycoprotein CD28 market?

North America and Europe are expected to be regional leaders due to strong research infrastructure.

Who are the top companies in the T Cell Specific Surface Glycoprotein CD28 market?

Top companies include pharmaceutical and biotechnology firms such as Pfizer and Novartis.

What future opportunities exist in the T Cell Specific Surface Glycoprotein CD28 market?

Future opportunities include development of new immunotherapies and expansion into emerging markets.

How will technology impact the T Cell Specific Surface Glycoprotein CD28 market?

Advances in gene editing and cell therapy will drive growth and innovation in the market.

What is the current regulatory landscape for the T Cell Specific Surface Glycoprotein CD28 market?

The regulatory landscape is complex, with strict guidelines from agencies such as the FDA and EMA.

T Cell Specific Surface Glycoprotein CD28 Market Metrics & Forecast Analysis 2033

T Cell Specific Surface Glycoprotein CD28 by Application (Plaque Psoriasis, Solid Tumor, Acute Renal Failure(ARF), Others), by Types (FPT-155, FR-104, Lulizumab Pegol, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

T Cell Specific Surface Glycoprotein CD28 Market Size | CAGR 10.2 Forecast 2033

T Cell Specific Surface Glycoprotein CD28 Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

T Cell Specific Surface Glycoprotein CD28 Market Overview

The T Cell Specific Surface Glycoprotein CD28 market refers to the industry focused on the research, development, and application of CD28, a crucial protein involved in the activation of T cells, which play a central role in the immune system. As the T Cell Specific Surface Glycoprotein CD28 market size is estimated to be around $1.3 billion, the growth outlook for this market is promising, with a projected market forecast indicating significant expansion over the forecast period. The industry expansion is expected to be driven by advancements in immunotherapy and the increasing understanding of the immune system's role in various diseases, including cancer and autoimmune disorders. The scope of this market encompasses the development of therapeutics, diagnostics, and research tools related to CD28.

Loading chart…

The current T Cell Specific Surface Glycoprotein CD28 market is experiencing a growth forecast with a compound annual growth rate (CAGR) of around 10%, driven by macro drivers such as the increasing prevalence of immune-related diseases and the growing demand for effective treatments. Key forces shaping the industry include technology shifts towards more targeted and personalized therapies, regulations supporting the development of innovative treatments, and competitive intensity among market players. The largest region for this market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the rapidly expanding healthcare sector and increasing investment in research and development. The T Cell Specific Surface Glycoprotein CD28 market size is anticipated to reach $2.5 billion by 2033, offering significant opportunities for industry expansion and growth.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Atox Bio Ltd; Bristol-Myers Squibb Co; Five Prime Therapeutics Inc; Johnson & Johnson; TheraMAB LLC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The T Cell Specific Surface Glycoprotein CD28 market is poised for significant growth, driven by advancements in immunotherapy and increasing demand for targeted treatments. The global T Cell Specific Surface Glycoprotein CD28 market size is expected to expand rapidly, with a promising growth forecast.

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR, are enabling the development of novel T Cell Specific Surface Glycoprotein CD28 therapies, driving market growth and expansion.

Increasing investments in research and development, coupled with rising government initiatives, are fueling the growth of the T Cell Specific Surface Glycoprotein CD28 market.

Restraints2 items

High development costs and regulatory hurdles are significant restraints in the T Cell Specific Surface Glycoprotein CD28 market, limiting the entry of new players and hindering market growth.

The complexity of immunotherapy treatments and potential side effects are also constraining factors, affecting the adoption of T Cell Specific Surface Glycoprotein CD28 therapies.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies presents a significant opportunity for the T Cell Specific Surface Glycoprotein CD28 market to expand its reach and offerings.

Collaborations and partnerships between biotechnology companies, research institutions, and pharmaceutical firms are expected to drive innovation and growth in the T Cell Specific Surface Glycoprotein CD28 market.

Challenges2 items

Ensuring the scalability and manufacturing efficiency of T Cell Specific Surface Glycoprotein CD28 therapies while maintaining their efficacy and safety is a significant challenge facing market players.

The competitive landscape of the T Cell Specific Surface Glycoprotein CD28 market is also expected to pose challenges, with multiple players vying for market share and differentiation.

Market Segmentation

Loading chart…

The T Cell Specific Surface Glycoprotein CD28 market can be segmented based on Application, which includes various sectors where CD28 is utilized. This segmentation contributes significantly to the overall market size, as different applications have distinct requirements and growth prospects. Understanding the T Cell Specific Surface Glycoprotein CD28 segmentation is crucial for industry players to tailor their strategies and capitalize on emerging opportunities.

The Types segment of the T Cell Specific Surface Glycoprotein CD28 market encompasses various subtypes, including [object Object] and [object Object]. Each subtype has its unique characteristics, advantages, and market demand. Analyzing these subtypes is essential to comprehend the market's overall dynamics and identify potential areas for growth and innovation. By examining the market taxonomy of CD28, researchers can better understand the complex interactions between different types and their applications.

T Cell Specific Surface Glycoprotein CD28 Segmentation Breakdown10 items

Application

Plaque Psoriasis

Solid Tumor

Acute Renal Failure(ARF)

Others

Types

FPT-155

FR-104

Lulizumab Pegol

Others

Regional Insights

Loading chart…

The T Cell Specific Surface Glycoprotein CD28 market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, established ecosystem maturity, high demographics awareness, and ongoing research investments; for Europe, regulatory support, growing demand for innovative treatments, and expanding infrastructure; for Asia Pacific, rising healthcare expenditures, increasing access to advanced therapies, and booming medical tourism; for Latin America, improving economic conditions, expanding healthcare access, and growing pharmaceutical investments; and for Middle East & Africa, increasing foreign investments, rising demand for specialty therapies, and developing healthcare infrastructure.

The regional forecast indicates a significant T Cell Specific Surface Glycoprotein CD28 market growth in Asia Pacific, driven by the region's large and growing population, increasing healthcare spending, and rising awareness of advanced therapies. In contrast, Middle East & Africa is expected to experience relatively slower growth due to infrastructural challenges and regulatory hurdles.

Competitive Landscape

The T Cell Specific Surface Glycoprotein CD28 market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on various levers such as pricing, distribution, and product innovation. The T Cell Specific Surface Glycoprotein CD28 competitive landscape is characterized by key players employing different strategies to gain a competitive edge. Regulatory approvals and certifications also play a crucial role in this market.

Companies in this market employ common strategies such as M&A, partnerships, and product launches to expand their offerings and reach. However, they face challenges like margin pressure and compliance costs, which can lead to commoditization and supply chain risks. To differentiate themselves, companies focus on technology, service models, and channel strength, as well as customization and cost advantages. Key players are adapting to these challenges by shifting their strategic focus.

Atox Bio Ltd: regional expansion

Bristol-Myers Squibb Co: innovation pipeline

Five Prime Therapeutics Inc: premium pricing

Johnson & Johnson: local manufacturing

TheraMAB LLC: OEM tie-ups

Other companies: vertical integration

Key T Cell Specific Surface Glycoprotein CD28 Companies5 items

Atox Bio Ltd

Bristol-Myers Squibb Co

Five Prime Therapeutics Inc

Johnson & Johnson

TheraMAB LLC

Market Ecosystem

The T Cell Specific Surface Glycoprotein CD28 ecosystem spans across upstream, midstream, and downstream segments, involving various stakeholders who create and capture value. Upstream participants, such as technology providers and suppliers, develop and provide essential components and technologies. Midstream players, including integrators and manufacturers, utilize these components to produce products. Downstream channels and end users ultimately receive and utilize these products, driving demand and influencing the ecosystem's dynamics.

Raw material/component suppliers — providing essential components

Technology providers — developing key technologies

OEMs / manufacturers — producing products

System integrators / EPCs — integrating products

Distributors / channel partners — delivering products

End users / buyers — driving demand

Regulators/standards bodies — setting standards and approvals

In the T Cell Specific Surface Glycoprotein CD28 ecosystem, value flows through the interactions and relationships among these participants. Control points, such as regulatory approvals and technology standards, can influence adoption and create dependency risks. Moreover, switching costs, partnerships, and interoperability requirements can impact the ecosystem's dynamics. A thorough value chain analysis is necessary to understand these complexities and identify potential bottlenecks. The ecosystem's characteristics may also differ by region, with varying levels of demand, regulatory frameworks, and market maturity.

Recent Industry Insights

The T Cell Specific Surface Glycoprotein CD28 market has witnessed significant developments over the last 12-18 months, shaping the industry's future. Recent partnerships have focused on advancing research and development in the field, while mergers and acquisitions have led to increased consolidation. Notably, product launches have centered around innovative therapies and treatments, with regulatory changes aiming to facilitate smoother approvals and faster time-to-market. A shift in consumer trends has also been observed, with a growing emphasis on personalized medicine and targeted therapies. Furthermore, funding rounds and expansions have been secured by key players, underscoring the industry's potential for growth. These developments are reflective of the evolving T Cell Specific Surface Glycoprotein CD28 industry trends, which are poised to drive the market forward.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the T Cell Specific Surface Glycoprotein CD28 market. The market attractiveness is high due to the growing demand for immunotherapies, while competitive intensity is moderate with key players investing in research and development. The long-term outlook for the T Cell Specific Surface Glycoprotein CD28 market outlook is promising, driven by innovations in cancer treatment and autoimmune diseases. The innovation landscape is evolving, with advancements in biotechnology and gene editing. However, the demand–supply balance is challenging, with fluctuations in clinical trial outcomes and regulatory approvals. Key risk factors include supply chain disruptions and regulatory changes.

12 items

1. Executive Summary

2. T Cell Specific Surface Glycoprotein CD28 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global T Cell Specific Surface Glycoprotein CD28 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global T Cell Specific Surface Glycoprotein CD28 Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global T Cell Specific Surface Glycoprotein CD28 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global T Cell Specific Surface Glycoprotein CD28 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global T Cell Specific Surface Glycoprotein CD28 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global T Cell Specific Surface Glycoprotein CD28 Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global T Cell Specific Surface Glycoprotein CD28 Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global T Cell Specific Surface Glycoprotein CD28 Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global T Cell Specific Surface Glycoprotein CD28 Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global T Cell Specific Surface Glycoprotein CD28 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global T Cell Specific Surface Glycoprotein CD28 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global T Cell Specific Surface Glycoprotein CD28 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global T Cell Specific Surface Glycoprotein CD28 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global T Cell Specific Surface Glycoprotein CD28 Market Competition by Key Manufacturers

9.1. Global T Cell Specific Surface Glycoprotein CD28 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global T Cell Specific Surface Glycoprotein CD28: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Atox Bio Ltd

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bristol-Myers Squibb Co

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Five Prime Therapeutics Inc

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Johnson & Johnson

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. TheraMAB LLC

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global T Cell Specific Surface Glycoprotein CD28 Market

Figure 4: Global T Cell Specific Surface Glycoprotein CD28 Market: Drivers

Figure 5: Global T Cell Specific Surface Glycoprotein CD28 Market: Challenges

Figure 6: Global T Cell Specific Surface Glycoprotein CD28 Market: Trends

Figure 7: Global T Cell Specific Surface Glycoprotein CD28 Market: Opportunity

Figure 8: Global T Cell Specific Surface Glycoprotein CD28 Market: Restraint

Figure 9: Global T Cell Specific Surface Glycoprotein CD28 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global T Cell Specific Surface Glycoprotein CD28 Market Value (USD Million) By Region

Figure 19: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global T Cell Specific Surface Glycoprotein CD28 Market Value (USD Million) By Region

Figure 27: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By: Regions (2032)

Figure 28: Global T Cell Specific Surface Glycoprotein CD28 Market Volume (K) By Region

Figure 29: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global T Cell Specific Surface Glycoprotein CD28 Market Value (USD Million) By Region

Figure 37: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By: Regions (2032)

Figure 38: Global T Cell Specific Surface Glycoprotein CD28 Market Volume (K) By Region

Figure 39: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global T Cell Specific Surface Glycoprotein CD28 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global T Cell Specific Surface Glycoprotein CD28 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global T Cell Specific Surface Glycoprotein CD28 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global T Cell Specific Surface Glycoprotein CD28 Market Value (USD Million) By Region

Table 14: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global T Cell Specific Surface Glycoprotein CD28 Market Volume (K) By Region

Table 31: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global T Cell Specific Surface Glycoprotein CD28 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global T Cell Specific Surface Glycoprotein CD28 Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global T Cell Specific Surface Glycoprotein CD28 Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Atox Bio Ltd Basic Information And Sales Area

Table 52: Atox Bio Ltd. Products Portfolio

Table 53: Bristol-Myers Squibb Co Basic Information And Sales Area

Table 54: Bristol-Myers Squibb Co. Products Portfolio

Table 55: Five Prime Therapeutics Inc Basic Information And Sales Area

Table 56: Five Prime Therapeutics Inc. Products Portfolio

Table 57: Johnson & Johnson Basic Information And Sales Area

Table 58: Johnson & Johnson. Products Portfolio

Table 59: TheraMAB LLC Basic Information And Sales Area

Table 60: TheraMAB LLC. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global T Cell Specific Surface Glycoprotein CD28 Market Value (USD Million) By Region

Table 70: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global T Cell Specific Surface Glycoprotein CD28 Market Volume (K) By Region

Table 87: Global T Cell Specific Surface Glycoprotein CD28 Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

T Cell Specific Surface Glycoprotein CD28 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Atox Bio Ltd; Bristol-Myers Squibb Co; Five Prime Therapeutics Inc; Johnson & Johnson; TheraMAB LLC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options